Stock · BIIB · Healthcare
United States · Large Cap · listed since 1991 · Revenue 12 mo. $9.9B
Price as of 11/06/2026
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally.
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Original text from the data provider
Summary
45.7 of 100
Mean of the six area values. Each area value is the mean of the stock's ranks among the companies in its sector. 50 is the middle of the sector, not a share of companies beaten.
Analysis
What the price requires
If free cash flow stays at €1.8B (2025), it supports €20.4B. The remaining €13.1B of the market value assume it grows 7.0% a year for 10 years and not at all afterwards.
Required FCF growth per year
7.0%
no growth afterwards
Price to operating cash flow 12.8×, within its usual range.
Middle half of 20 quarters: 10.1× to 20.4×, median 12.5×.
Measures only against its own past, not against what the company is worth. Price as of 11/06/2026.
with respect to the priced-in expectation
with respect to the priced-in expectation
Since the last quarter
Q1 → Q2 2026
2 more unchanged: Revenue, 12 mo., Shares outstanding
Derivation
Each area value is the average of its metrics' ranks within the sector (0 to 100, 50 is the middle). For metrics where lower is better, the rank is mirrored. The overall value is the average of the area values.
Price as of 11/06/2026.
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Return on equity | 7.08% | 11.52% | Rank 28 |
| Return on capital (Greenblatt) | 20.99% | 32.55% | Rank 28 |
| EBIT margin | 19.14% | 18.31% | Rank 55 |
| FCF margin | 20.90% | 14.12% | Rank 72 |
| Gross margin | 70.47% | 60.99% | Rank 66 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Revenue growth, 1 year | 1.39% | 8.04% | Rank 17 |
| Earnings growth, 3 years per year | −24.96% | 5.44% | Rank 8 |
| Earnings growth, 5 years per year | −18.69% | 7.00% | Rank 4 |
| Sustainable growth (ROE × retained earnings) | 1.57% | 3.66% | Rank 19 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Earnings yield | 3.55% | 2.90% | Rank 62 |
| FCF yield | 5.48% | 3.63% | Rank 77 |
| EV/saleslower is better | 4.13 | 4.03 | Rank 48 |
| EV/EBITlower is better | 21.58 | 21.73 | Rank 52 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Share price, 1 year | 48.84% | 8.66% | Rank 89 |
| Share price, 6 months | 28.86% | 24.27% | Rank 63 |
| Share price, 3 months | 24.56% | 15.42% | Rank 78 |
| Distance from 52-week high | −2.40% | −7.35% | Rank 72 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Accruals (Sloan)lower is better | 1.60% | 0.30% | Rank 40 |
| Change in share countlower is better | 0.55% | 0.00% | Rank 20 |
| Dividend streak in years | – | 10 | Rank 13 |
| Price reaction to results, market-adjusted | −3.67% | 0.05% | Rank 21 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Equity ratio | 62.01% | 48.40% | Rank 69 |
| Net debt/EBITDAlower is better | 1.06 | 1.11 | Rank 51 |
| Debt to equitylower is better | 0.38 | 0.48 | Rank 55 |
| Volatility, 1 yearlower is better | 34.28% | 31.42% | Rank 41 |
Ten years in figures
| Year | Revenue, $B | EBIT margin | FCF, $B | Shares | Net debt, $B |
|---|---|---|---|---|---|
| 2016 | 11.4 | 45.0% | 3.9 | 219M | 4.2 |
| 2017 | 12.3 | 43.6% | 3.7 | 213M | 4.4 |
| 2018 | 13.5 | 43.8% | 5.3 | 205M | 4.7 |
| 2019 | 14.4 | 49.0% | 6.6 | 187M | 3.5 |
| 2020 | 13.4 | 34.2% | 3.7 | 161M | 6.5 |
| 2021 | 11.0 | 25.4% | 3.3 | 150M | 5.3 |
| 2022 | 10.2 | 28.4% | 1.1 | 146M | 3.2 |
| 2023 | 9.8 | 21.3% | 1.2 | 146M | 6.3 |
| 2024 | 9.7 | 25.7% | 2.5 | 146M | 4.3 |
| 2025 | 9.8 | 19.1% | 2.1 | 147M | 3.9 |
3 of 7 StockScorer Score rules met · How the score is built
Biogen Inc mainly meets criteria in the Valuation category. Result from 18 strategies checked.
Biogen Inc is rated here with the StockScorer Score strategy, the flagship rule set. It compares return and cash-flow metrics with the median of the company's own sector and checks growth and price trend.
3 of 7 rules met
5 of 11 points
Detail data
Excerpt from 18 strategies checked. The full evaluation is visible after a free sign-up.
With a free account, you can see the match across all strategies checked in one complete overview.
Selected fundamental metrics for Biogen Inc.
| Metric | Stock | Sector |
|---|---|---|
| P/E ratio | 28.2 | 30.0 |
| P/B ratio | 2.0 | 4.8 |
| Return on equity (ROE) | 7.1% | 11.5% |
| Equity ratio | 62.0% | 48.4% |
| Debt-to-equity (D/E) | 0.38 | 0.48 |
| Dividend yield | 0.0% | 1.3% |
How comparable stocks in the same sector score in the StockScorer model.
| Symbol | Company | Rating |
|---|---|---|
| BIIB | Biogen Incthis page | |
| BMY | Bristol-Myers Squibb Company | High7.3 |
| 4578.T | Otsuka Holdings Ltd | locked |
| 4568.T | Daiichi Sankyo Co. Ltd. | locked |
| 4503.T | Astellas Pharma Inc. | locked |
| ORNBV.HE | Orion Oyj B | locked |
Signed up in 30 seconds, free.
Learn more about the metrics in the metrics glossary or all rated stocks in the stock overview.
How StockScorer rates every stock is explained on the methodology page.